-
ABOUT USThe company is a professional API manufacturer established and developed by Shijiazhuang No.4 Pharmaceutical Group to actively promote the development strategy of "API + preparation"
-
INNOVATIONDevelops fine, series, high-end API and innovative API intermediates with high added value through overcoming key technologies such as API synthesis to build variety competition advantages.
-
PRODUCTSWith the annual production 500MT of hydroxyethyl starch , 500MT of azithromycin , we are ranking in the API professional enterprises in Hebei Province and even in China .
-
RECRUITGuolong has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities
-
CONTACTAdhering to the "love the people with quality, formed the base with integrity" business philosophy, is committed to developing the domestic high-end market and the international market.
2023-03-13
Like! Lü Xiaolong, a post-00s employee at Guangxiang Pharmaceutical, part of Shijiazhuang Fourth Pharmaceutical Group, has successfully donated hematopoietic stem cells.
On the morning of February 27, in the hematopoietic stem cell collection room of the Third Hospital of Hebei Medical University, after more than five hours of collection, a young man born in the 2000s successfully donated 395 milliliters of hematopoietic stem cell suspension. These “seeds of life,” destined for distant recipients, carry with them profound love and the hope of renewed vitality. This young man from the 2000s is Lü Xiaolong, who works in the warehousing service department of Hebei Guangxiang Pharmaceutical Co., Ltd., part of Shijiazhuang Sihua Pharmaceutical Group. He is also the second employee from this group to successfully donate hematopoietic stem cells.
2022-11-13
The “Little Giant” City Profile—Cangzhou, Hebei: Anchoring on Specialization, Excellence, and Innovation to Boost the Momentum of “Little Giants”
Currently, Hebei Guangxiang Pharmaceutical Co., Ltd. has embarked on the journey to become a nationally recognized “Little Giant” enterprise specializing in niche, sophisticated, and innovative products. The company has identified untapped market segments and is poised to deepen its expertise in specialty pharmaceutical ingredients. Leveraging a series of supportive policies at the national, provincial, and municipal levels aimed at fostering the development of the biopharmaceutical industry, Guangxiang is steadily increasing its R&D investment and continuously driving its business forward to reach new heights and achieve breakthroughs.
2022-05-23
Shi Si Yao accelerates the high-quality development of active pharmaceutical ingredients and moves toward becoming a leading API manufacturer.
Against the backdrop of implementing the country’s new development philosophy and accelerating the transition from a major pharmaceutical producer to a powerful pharmaceutical nation, China’s leading pharmaceutical company, Shijiazhuang Fourth Pharmaceutical Group (referred to as “Shijiazhuang Fourth Pharma”), is vigorously pursuing a “API + Finished Dosage Form” development strategy. Through strategic capital partnerships, acquisitions, and restructuring, the company is actively expanding its upstream and downstream industrial chains, enhancing its competitiveness in both domestic and international markets, and injecting fresh momentum into the accelerated development of its API business segment. A series of significant initiatives are propelling Shijiazhuang Fourth Pharmaceutical Group toward its goal of becoming a leading API manufacturer.
Our flagship product, caffeine, and other related products have all seen robust growth in both production and sales. Seven new specialty pharmaceutical ingredients—including hexamethylenetetramine and ornidazole—are set to receive approval and launch soon. In the first quarter, our core business revenue achieved triple-digit growth... Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has delivered an impressive “combination punch,” ushering in a strong start to its innovative development.
20
2022/04
![[Special Report] The Spirit of the Sixth Plenary Session at Shisi Pharmaceutical Group’s Guangxiang Pharmaceutical | Innovation and Bold Pioneering: Products Go Global](https://omo-oss-image.thefastimg.com/portal-saas/pg2026012819511183729/cms/image/0f16849a-1bf9-4699-8030-30872b3ce0c6.jpg "[Special Report] The Spirit of the Sixth Plenary Session at Shisi Pharmaceutical Group’s Guangxiang Pharmaceutical | Innovation and Bold Pioneering: Products Go Global")
Sharing feelings, exchanging insights, and talking about the future... On November 23, in the Party-Mass Activity Room of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, 20 Party members sat together in a circle, each taking turns to express their thoughts and experiences on studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee. The atmosphere at the scene was fervent and enthusiastic, and everyone felt full of confidence about the future.
20
2022/01
Guangxiang Pharmaceutical: Building a Model of “Green Pharmaceutical Production” with New Concepts
Shi Si Yao Group’s Hebei Guangxiang Pharmaceutical is seizing the opportunities presented by the coordinated development of the Beijing-Tianjin-Hebei region. Relying heavily on the group’s strong financial resources, robust R&D capabilities, and established brand reputation, the company is investing in the Beijing-Cangzhou Bohai New Area Biopharmaceutical Industrial Park to build a mega-scale pharmaceutical enterprise specializing in active pharmaceutical ingredients, intermediate compounds, and biopharmaceutical formulations.
03
2019/12
SERVICE HOTLINE
Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province
Mobile site
E code
Business license